\
&
Contact us
\
&
Contact us
Starts in 1 month from now
LocationBrussels
This event aims to inform potential applicants about the upcoming 6th call of the Defence-related Research Action DEFRA. It also seeks to provide networking opportunities for participants.
BELSPO and the RHID will launch the 6th call within the framework of DEFRA.
Information days are scheduled for 27 and 28 January 2026 at the Royal Military Academy.
The event will cover the context, scope, and modalities of the call, also allowing applicants to connect and explore collaboration opportunities. More details about the programme and registration will be available at the end of December 2025.
Themes
More information: DEFRA call 2026
Provisional calendar *
| Activity | Deadline |
|---|---|
| Information session | 27 and 28 January 2026 |
| Deadline Pre-proposals | 19 February 2026 (14h00) |
| Communication of evaluation result pre-proposals | 23 March 2026 |
| Deadline Full proposals | 4 May 2026 (14h00) |
| Remote scientific peer review evaluation | 5 May - 1 June 2026 |
| Feedback to applicants in preparation of panel meeting (consensus reports & questions to applicants) |
30 June 2026 |
| Written feedback by applicants (answers) | 31 July 2026 |
| Panel evaluation, incl. interviews with the applicants | Between 10 August and 2 September 2026 |
| Selection proposal formulated by the scientific committee of the RHID | 10 September 2026 |
| Final selection of proposals by the board of directors of the RHID and allocation of projects | 1 October 2026 |
| Communication of results to applicants | 6 October 2026 |
| Signature contracts | 16 November 2026 |
*Exact dates are to be confirmed
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
